Triple-negative breast cancer (TNBC), which is clinically defined by the absence of expression of human epidermal growth factor receptor 2 (HER2), progesterone receptor (PR), and estrogen receptor (ER), contributes to approximately 15–20% of all breast cancer cases. This evidence concerns the gene ERBB2 and breast carcinoma.